marketcaparena
Search

    BDX

    BECTON DICKINSON & CO

    Company overview

    Market capitalization
    $50.07B
    Employees
    60,000
    Latest publication
    2026-09-29
    About BECTON DICKINSON & CO

    Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ3 20262026-06-30 · USDQ1 20262025-12-31 · USDQ4 20252025-09-30 · USDQ3 20252025-06-30 · USDQ2 20252025-03-31 · USDQ1 20252024-12-31 · USDQ4 20242024-09-30 · USDQ3 20242024-06-30 · USD
    Total Revenue4,983,000,000USD5,252,000,000USD5,890,000,000USD5,509,000,000USD5,272,000,000USD5,168,000,000USD5,437,000,000USD4,990,000,000USD
    Cost Of Revenue2,668,000,000USD2,908,000,000USD3,092,000,000USD2,875,000,000USD3,015,000,000USD2,933,000,000USD2,950,000,000USD2,683,000,000USD
    Gross Profit2,315,000,000USD2,344,000,000USD2,798,000,000USD2,634,000,000USD2,257,000,000USD2,235,000,000USD2,487,000,000USD2,307,000,000USD
    Research Development258,000,000USD318,000,000USD322,000,000USD297,000,000USD302,000,000USD343,000,000USD302,000,000USD299,000,000USD
    Selling General Administrative1,261,000,000USD1,432,000,000USD1,366,000,000USD1,320,000,000USD1,273,000,000USD1,318,000,000USD1,256,000,000USD1,196,000,000USD
    Total Operating Expenses1,652,000,000USD1,750,000,000USD2,102,000,000USD1,752,000,000USD1,711,000,000USD1,782,000,000USD1,865,000,000USD1,705,000,000USD
    Operating Income663,000,000USD594,000,000USD697,000,000USD882,000,000USD546,000,000USD453,000,000USD622,000,000USD602,000,000USD
    Total Other Income Expense Net-109,000,000USD-107,000,000USD-187,000,000USD-179,000,000USD-183,000,000USD-147,000,000USD-108,000,000USD-102,000,000USD
    Interest Income4,000,000USD4,000,000USD150,000,000USD5,000,000USD5,000,000USD23,000,000USD55,000,000USD48,000,000USD
    Interest Expense132,000,000USD107,000,000USD155,000,000USD152,000,000USD151,000,000USD155,000,000USD155,000,000USD137,000,000USD
    Income Before Tax554,000,000USD487,000,000USD510,000,000USD703,000,000USD363,000,000USD306,000,000USD514,000,000USD500,000,000USD
    Income Tax Expense102,000,000USD105,000,000USD17,000,000USD129,000,000USD55,000,000USD3,000,000USD114,000,000USD13,000,000USD
    Discontinued Operations-74,000,000USD———————
    Net Income377,000,000USD382,000,000USD493,000,000USD574,000,000USD308,000,000USD303,000,000USD400,000,000USD487,000,000USD
    Net Interest Income—-149,000,000USD-150,000,000USD-147,000,000USD-146,000,000USD-132,000,000USD-100,000,000USD-89,000,000USD
    Tax Provision—11,000,000USD17,000,000USD129,000,000USD55,000,000USD3,000,000USD114,000,000USD13,000,000USD
    Net Income From Continuing Ops—382,000,000USD493,000,000USD574,000,000USD308,000,000USD303,000,000USD400,000,000USD487,000,000USD
    Ebit—594,000,000USD665,000,000USD855,000,000USD514,000,000USD461,000,000USD669,000,000USD637,000,000USD
    Ebitda—1,208,000,000USD1,294,000,000USD1,473,000,000USD1,122,000,000USD1,068,000,000USD1,255,000,000USD1,205,000,000USD
    Depreciation And Amortization—614,000,000USD629,000,000USD618,000,000USD608,000,000USD607,000,000USD586,000,000USD568,000,000USD
    Reconciled Depreciation—614,000,000USD629,000,000USD618,000,000USD608,000,000USD607,000,000USD586,000,000USD568,000,000USD
    Net Income Applicable To Common Shares—382,000,000USD493,000,000USD574,000,000USD308,000,000USD303,000,000USD400,000,000USD—
    Unclassified Operating Expenses——414,000,000USD135,000,000USD136,000,000USD121,000,000USD307,000,000USD210,000,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-09-30 · USDFY 20242024-09-30 · USDFY 20232023-09-30 · USDFY 20222022-09-30 · USDFY 20182018-09-30 · USDFY 20172017-09-30 · USDFY 20162016-09-30 · USDFY 20152015-09-30 · USD
    Total Revenue21,839,000,000USD20,178,000,000USD19,372,000,000USD18,870,000,000USD15,983,000,000USD12,093,000,000USD12,483,000,000USD10,282,000,000USD
    Cost Of Revenue11,915,000,000USD11,053,000,000USD11,202,000,000USD10,393,000,000USD8,714,000,000USD6,128,000,000USD6,492,000,000USD5,587,000,000USD
    Gross Profit9,924,000,000USD9,125,000,000USD8,170,000,000USD8,477,000,000USD7,269,000,000USD5,965,000,000USD5,991,000,000USD4,695,000,000USD
    Research Development1,264,000,000USD1,190,000,000USD1,237,000,000USD1,256,000,000USD1,004,000,000USD770,000,000USD828,000,000USD632,000,000USD
    Selling General Administrative5,278,000,000USD4,857,000,000USD4,719,000,000USD4,709,000,000USD13,000,000USD44,000,000USD3,005,000,000USD2,563,000,000USD
    Unclassified Operating Expenses805,000,000USD681,000,000USD103,000,000USD230,000,000USD727,000,000USD720,000,000USD728,000,000USD426,000,000USD
    Total Operating Expenses7,347,000,000USD6,728,000,000USD6,059,000,000USD6,195,000,000USD5,760,000,000USD4,443,000,000USD4,561,000,000USD3,621,000,000USD
    Operating Income2,578,000,000USD2,397,000,000USD2,111,000,000USD2,282,000,000USD1,509,000,000USD1,522,000,000USD1,430,000,000USD1,074,000,000USD
    Interest Income38,000,000USD163,000,000USD49,000,000USD16,000,000USD65,000,000USD76,000,000USD21,000,000USD405,000,000USD
    Interest Expense613,000,000USD528,000,000USD452,000,000USD398,000,000USD706,000,000USD521,000,000USD388,000,000USD371,000,000USD
    Net Interest Income-575,000,000USD-365,000,000USD-403,000,000USD-382,000,000USD-641,000,000USD-445,000,000USD-367,000,000USD—
    Income Before Tax1,882,000,000USD2,005,000,000USD1,662,000,000USD1,783,000,000USD1,173,000,000USD976,000,000USD1,074,000,000USD739,000,000USD
    Income Tax Expense204,000,000USD300,000,000USD132,000,000USD148,000,000USD862,000,000USD-124,000,000USD98,000,000USD44,000,000USD
    Tax Provision203,000,000USD300,000,000USD132,000,000USD148,000,000USD862,000,000USD-124,000,000USD97,000,000USD44,000,000USD
    Net Income1,678,000,000USD1,705,000,000USD1,484,000,000USD1,779,000,000USD311,000,000USD1,100,000,000USD976,000,000USD695,000,000USD
    Net Income From Continuing Ops1,678,000,000USD1,705,000,000USD1,530,000,000USD1,635,000,000USD311,000,000USD1,100,000,000USD976,000,000USD695,000,000USD
    Ebit2,495,000,000USD2,533,000,000USD2,114,000,000USD2,181,000,000USD1,879,000,000USD1,497,000,000USD1,462,000,000USD1,110,000,000USD
    Ebitda4,957,000,000USD4,819,000,000USD4,402,000,000USD4,410,000,000USD3,857,000,000USD2,585,000,000USD2,576,000,000USD2,001,000,000USD
    Depreciation And Amortization2,462,000,000USD2,286,000,000USD2,288,000,000USD2,229,000,000USD1,978,000,000USD1,088,000,000USD1,114,000,000USD891,000,000USD
    Reconciled Depreciation2,462,000,000USD2,286,000,000USD2,288,000,000USD2,229,000,000USD1,978,000,000USD1,088,000,000USD——
    Total Other Income Expense Net-696,000,000USD-392,000,000USD-449,000,000USD-499,000,000USD-336,000,000USD-546,000,000USD-356,000,000USD-335,000,000USD
    Net Income Applicable To Common Shares1,678,000,000USD1,705,000,000USD1,424,000,000USD1,689,000,000USD159,000,000USD1,030,000,000USD976,000,000USD695,000,000USD
    Discontinued Operations——-46,000,000USD144,000,000USD————
    Non Operating Income Net Other———-101,000,000USD383,000,000USD19,000,000USD32,000,000USD—
    Selling And Marketing Expenses————4,016,000,000USD2,909,000,000USD——
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ3 20262026-06-30 · USDQ2 20262026-03-31 · USDQ1 20262025-12-31 · USDQ4 20252025-09-30 · USDQ3 20252025-06-30 · USDQ2 20252025-03-31 · USDQ1 20252024-12-31 · USDQ4 20242024-09-30 · USD
    Total Assets50,731,000,000USD50,832,000,000USD54,841,000,000USD55,325,000,000USD54,902,000,000USD54,467,000,000USD54,665,000,000USD57,286,000,000USD
    Cash And Equivalents708,000,000USD—740,000,000USD641,000,000USD735,000,000USD667,000,000USD711,000,000USD1,717,000,000USD
    Total Current Assets8,139,000,000USD8,012,000,000USD9,189,000,000USD9,255,000,000USD8,997,000,000USD8,666,000,000USD8,659,000,000USD10,468,000,000USD
    Other Current Assets1,595,000,000USD1,634,000,000USD1,561,000,000USD1,508,000,000USD1,348,000,000USD1,231,000,000USD1,433,000,000USD1,291,000,000USD
    Other Non Current Assets2,546,000,000USD———————
    Total Liabilities26,315,000,000USD———————
    Total Current Liabilities9,404,000,000USD8,507,000,000USD8,761,000,000USD8,313,000,000USD8,160,000,000USD7,691,000,000USD7,664,000,000USD8,956,000,000USD
    Other Non Current Liabilities2,394,000,000USD———————
    Total Stockholder Equity24,416,000,000USD24,133,000,000USD25,282,000,000USD25,390,000,000USD25,473,000,000USD25,241,000,000USD25,204,000,000USD25,889,000,000USD
    Total Equity Including Noncontrolling Interest24,416,000,000USD———————
    Long Term Debt13,511,000,000USD14,706,000,000USD16,916,000,000USD17,621,000,000USD17,531,000,000USD17,666,000,000USD17,440,000,000USD17,940,000,000USD
    Net Receivables2,364,000,000USD2,205,000,000USD2,508,000,000USD2,994,000,000USD2,943,000,000USD3,029,000,000USD2,638,000,000USD3,033,000,000USD
    Inventory3,316,000,000USD3,357,000,000USD4,085,000,000USD3,894,000,000USD3,949,000,000USD3,723,000,000USD3,860,000,000USD3,843,000,000USD
    Property Plant Equipment Net6,083,000,000USD6,082,000,000USD6,972,000,000USD6,997,000,000USD6,818,000,000USD6,646,000,000USD6,602,000,000USD6,821,000,000USD
    Goodwill25,944,000,000USD———————
    Intangible Assets448,000,000USD8,348,000,000USD9,025,000,000USD2,994,000,000USD9,788,000,000USD10,133,000,000USD10,489,000,000USD10,917,000,000USD
    Accounts Payable6,107,000,000USD—6,138,000,000USD1,974,000,000USD6,350,000,000USD6,087,000,000USD6,347,000,000USD1,896,000,000USD
    Short Term Debt3,297,000,000USD2,573,000,000USD2,623,000,000USD1,560,000,000USD1,810,000,000USD1,604,000,000USD1,318,000,000USD2,312,000,000USD
    Common Stock371,000,000USD371,000,000USD371,000,000USD371,000,000USD371,000,000USD371,000,000USD371,000,000USD371,000,000USD
    Retained Earnings17,509,000,000USD17,391,000,000USD16,704,000,000USD16,622,000,000USD16,426,000,000USD16,150,000,000USD16,141,000,000USD16,139,000,000USD
    Accumulated Other Comprehensive Income-1,649,000,000USD-1,737,000,000USD-1,857,000,000USD-1,870,000,000USD-1,813,000,000USD-1,716,000,000USD-1,676,000,000USD-1,732,000,000USD
    Total Liab—26,699,000,000USD29,559,000,000USD29,936,000,000USD29,429,000,000USD29,226,000,000USD29,461,000,000USD31,397,000,000USD
    Other Current Liab—5,934,000,000USD—4,779,000,000USD6,753,000,000USD6,087,000,000USD-1,000,000USD4,580,000,000USD
    Capital Stock—371,000,000USD371,000,000USD371,000,000USD371,000,000USD371,000,000USD371,000,000USD371,000,000USD
    Good Will—25,955,000,000USD26,620,000,000USD33,023,000,000USD26,597,000,000USD26,444,000,000USD26,329,000,000USD26,465,000,000USD
    Cash—813,000,000USD1,024,000,000USD851,000,000USD735,000,000USD667,000,000USD711,000,000USD1,856,000,000USD
    Cash And Short Term Investments—816,000,000USD1,035,000,000USD859,000,000USD757,000,000USD683,000,000USD728,000,000USD2,301,000,000USD
    Net Debt—16,466,000,000USD18,515,000,000USD18,330,000,000USD18,606,000,000USD18,603,000,000USD18,047,000,000USD19,730,000,000USD
    Short Long Term Debt—2,573,000,000USD2,623,000,000USD1,560,000,000USD1,810,000,000USD1,604,000,000USD1,318,000,000USD2,170,000,000USD
    Short Long Term Debt Total—17,279,000,000USD19,539,000,000USD19,181,000,000USD19,341,000,000USD19,270,000,000USD18,758,000,000USD21,586,000,000USD
    Short Term Investments—3,000,000USD11,000,000USD8,000,000USD22,000,000USD16,000,000USD17,000,000USD445,000,000USD
    Property Plant Equipment Gross—13,552,000,000USD15,237,000,000USD15,113,000,000USD14,854,000,000USD14,409,000,000USD14,156,000,000USD14,378,000,000USD
    Common Stock Shares Outstanding—280,640,000shares285,074,627shares287,118,000shares288,693,000shares289,193,000shares290,389,000shares290,602,000shares
    Non Current Assets Total—42,819,000,000USD45,652,000,000USD46,070,000,000USD45,905,000,000USD45,800,000,000USD46,005,000,000USD46,818,000,000USD
    Non Current Liabilities Total—18,192,000,000USD20,798,000,000USD21,623,000,000USD21,269,000,000USD21,535,000,000USD21,797,000,000USD22,441,000,000USD
    Non Current Liabilities Other—2,461,000,000USD2,815,000,000USD2,932,000,000USD2,830,000,000USD2,998,000,000USD3,418,000,000USD3,559,000,000USD
    Non Currrent Assets Other—2,434,000,000USD3,035,000,000USD3,056,000,000USD2,702,000,000USD2,577,000,000USD2,585,000,000USD2,615,000,000USD
    Net Working Capital—-495,000,000USD428,000,000USD942,000,000USD837,000,000USD975,000,000USD995,000,000USD1,512,000,000USD
    Unclassified Current Liabilities—-2,573,000,000USD-2,623,000,000USD-1,560,000,000USD-8,563,000,000USD-7,691,000,000USD-1,319,000,000USD-2,002,000,000USD
    Unclassified Non Current Liabilities—1,025,000,000USD1,067,000,000USD1,070,000,000USD908,000,000USD871,000,000USD939,000,000USD942,000,000USD
    Unclassified Equity—7,737,000,000USD9,693,000,000USD9,896,000,000USD10,118,000,000USD10,065,000,000USD9,997,000,000USD10,740,000,000USD
    Other Assets——3,035,000,000USD3,056,000,000USD2,702,000,000USD1,000,000USD1,000,000USD2,615,000,000USD
    Unclassified Non Current Assets——-3,035,000,000USD-3,056,000,000USD-2,702,000,000USD——-2,615,000,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-09-30 · USDFY 20242024-09-30 · USDFY 20232023-09-30 · USDFY 20222022-09-30 · USDFY 20212021-09-30 · USDFY 20202020-09-30 · USDFY 20192019-09-30 · USDFY 20182018-09-30 · USD
    Total Assets55,325,000,000USD57,286,000,000USD52,780,000,000USD52,934,000,000USD53,880,000,000USD54,012,000,000USD51,842,000,000USD53,904,000,000USD
    Intangible Assets2,994,000,000USD10,917,000,000USD10,947,000,000USD12,309,000,000USD12,784,000,000USD13,813,000,000USD14,977,000,000USD16,441,000,000USD
    Other Current Assets1,508,000,000USD1,291,000,000USD1,445,000,000USD1,559,000,000USD1,341,000,000USD983,000,000USD1,174,000,000USD1,484,000,000USD
    Total Liab29,936,000,000USD31,397,000,000USD26,983,000,000USD27,652,000,000USD30,203,000,000USD30,247,000,000USD30,683,000,000USD32,910,000,000USD
    Total Stockholder Equity25,390,000,000USD25,889,000,000USD25,797,000,000USD25,282,000,000USD23,677,000,000USD23,765,000,000USD21,082,000,000USD20,994,000,000USD
    Other Current Liab4,779,000,000USD4,580,000,000USD3,602,000,000USD3,658,000,000USD4,083,000,000USD3,631,000,000USD3,114,000,000USD3,166,000,000USD
    Common Stock371,000,000USD371,000,000USD371,000,000USD365,000,000USD365,000,000USD365,000,000USD347,000,000USD347,000,000USD
    Capital Stock371,000,000USD371,000,000USD371,000,000USD367,000,000USD367,000,000USD367,000,000USD349,000,000USD349,000,000USD
    Retained Earnings16,622,000,000USD16,139,000,000USD15,535,000,000USD15,157,000,000USD13,826,000,000USD12,791,000,000USD12,912,000,000USD12,594,000,000USD
    Good Will33,023,000,000USD26,465,000,000USD24,522,000,000USD24,621,000,000USD23,886,000,000USD23,620,000,000USD23,376,000,000USD23,600,000,000USD
    Other Assets2,171,000,000USD1,739,000,000USD2,078,000,000USD3,000,000USD1,000,000USD1,269,000,000USD1,000,000USD-1,000,000USD
    Cash851,000,000USD1,856,000,000USD1,416,000,000USD1,159,000,000USD2,392,000,000USD2,825,000,000USD536,000,000USD1,140,000,000USD
    Cash And Equivalents641,000,000USD1,717,000,000USD1,416,000,000USD1,006,000,000USD2,283,000,000USD2,825,000,000USD536,000,000USD1,140,000,000USD
    Cash And Short Term Investments859,000,000USD2,301,000,000USD1,424,000,000USD1,167,000,000USD2,404,000,000USD2,845,000,000USD566,000,000USD1,157,000,000USD
    Total Current Assets9,255,000,000USD10,468,000,000USD8,676,000,000USD8,141,000,000USD8,838,000,000USD8,969,000,000USD6,644,000,000USD7,411,000,000USD
    Total Current Liabilities8,313,000,000USD8,956,000,000USD6,641,000,000USD7,811,000,000USD6,626,000,000USD5,836,000,000USD5,655,000,000USD7,216,000,000USD
    Net Debt18,330,000,000USD19,730,000,000USD15,343,000,000USD15,792,000,000USD16,032,000,000USD15,105,000,000USD18,854,000,000USD20,355,000,000USD
    Short Term Debt1,560,000,000USD2,312,000,000USD1,258,000,000USD2,297,000,000USD626,000,000USD706,000,000USD1,309,000,000USD2,601,000,000USD
    Short Long Term Debt1,560,000,000USD2,170,000,000USD1,141,000,000USD2,179,000,000USD500,000,000USD707,000,000USD1,309,000,000USD2,601,000,000USD
    Short Long Term Debt Total19,181,000,000USD21,586,000,000USD16,824,000,000USD16,951,000,000USD18,424,000,000USD17,930,000,000USD19,390,000,000USD21,495,000,000USD
    Long Term Debt17,621,000,000USD17,940,000,000USD14,738,000,000USD13,886,000,000USD17,110,000,000USD17,224,000,000USD18,081,000,000USD18,894,000,000USD
    Short Term Investments8,000,000USD445,000,000USD8,000,000USD8,000,000USD12,000,000USD20,000,000USD30,000,000USD17,000,000USD
    Net Receivables2,994,000,000USD3,033,000,000USD2,534,000,000USD2,191,000,000USD2,350,000,000USD2,398,000,000USD2,345,000,000USD2,319,000,000USD
    Inventory3,894,000,000USD3,843,000,000USD3,273,000,000USD3,224,000,000USD2,743,000,000USD2,743,000,000USD2,579,000,000USD2,451,000,000USD
    Accounts Payable1,974,000,000USD1,896,000,000USD1,641,000,000USD1,699,000,000USD1,739,000,000USD1,355,000,000USD1,092,000,000USD1,106,000,000USD
    Property Plant Equipment Net6,997,000,000USD6,821,000,000USD6,557,000,000USD6,012,000,000USD6,003,000,000USD5,923,000,000USD5,659,000,000USD5,375,000,000USD
    Property Plant Equipment Gross15,113,000,000USD14,378,000,000USD13,578,000,000USD12,414,000,000USD12,942,000,000USD5,923,000,000USD5,659,000,000USD5,375,000,000USD
    Accumulated Other Comprehensive Income-1,870,000,000USD-1,732,000,000USD-1,548,000,000USD-1,488,000,000USD-2,088,000,000USD-2,548,000,000USD-2,283,000,000USD-1,909,000,000USD
    Common Stock Shares Outstanding287,118,000shares291,009,000shares288,392,000shares287,364,000shares292,089,000shares282,402,000shares274,775,000shares264,621,000shares
    Non Current Assets Total46,070,000,000USD46,818,000,000USD44,104,000,000USD44,790,000,000USD45,041,000,000USD45,043,000,000USD45,100,000,000USD46,494,000,000USD
    Non Current Liabilities Total21,623,000,000USD22,441,000,000USD20,342,000,000USD19,841,000,000USD23,563,000,000USD24,411,000,000USD25,028,000,000USD25,694,000,000USD
    Non Current Liabilities Other2,932,000,000USD3,559,000,000USD4,582,000,000USD1,000,000USD6,453,000,000USD7,188,000,000USD-1,000,000USD6,799,000,000USD
    Non Currrent Assets Other3,056,000,000USD2,615,000,000USD2,078,000,000USD1,848,000,000USD2,368,000,000USD1,687,000,000USD1,088,000,000USD1,078,000,000USD
    Net Working Capital942,000,000USD1,512,000,000USD2,035,000,000USD330,000,000USD2,212,000,000USD3,133,000,000USD1,009,000,000USD195,000,000USD
    Unclassified Non Current Assets-2,171,000,000USD-1,739,000,000USD-2,078,000,000USD——-1,269,000,000USD——
    Unclassified Current Liabilities-1,560,000,000USD-2,002,000,000USD-1,001,000,000USD-2,022,000,000USD-322,000,000USD-563,000,000USD-1,169,000,000USD-2,601,000,000USD
    Unclassified Non Current Liabilities1,070,000,000USD942,000,000USD-4,169,000,000USD—-6,453,000,000USD-6,852,000,000USD—-6,799,000,000USD
    Unclassified Equity9,896,000,000USD10,740,000,000USD11,068,000,000USD19,211,000,000USD18,930,000,000USD18,928,000,000USD15,947,000,000USD15,856,000,000USD
    Other Liab——5,191,000,000USD5,936,000,000USD6,453,000,000USD6,851,000,000USD6,948,000,000USD6,800,000,000USD
    Current Deferred Revenue——-1,641,000,000USD—-1,793,000,000USD-1,355,000,000USD-1,092,000,000USD343,000,000USD
    Net Tangible Assets——-9,674,000,000USD-11,631,000,000USD-13,007,000,000USD-13,671,000,000USD-17,275,000,000USD-19,048,000,000USD
    Treasury Stock———-8,330,000,000USD-7,723,000,000USD-6,138,000,000USD-6,190,000,000USD-6,243,000,000USD
    Deferred Long Term Liab———————0USD
    Additional Paid In Capital———————0USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow YTD

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ3 20262026-06-30 · USD
    Net Income449,000,000USD
    Depreciation1,697,000,000USD
    Stock Based Compensation204,000,000USD
    Deferred Income Tax-118,000,000USD
    Other Non Cash Items139,000,000USD
    Unclassified Operating Cash Flow77,000,000USD
    Change In Working Capital-542,000,000USD
    Operating Cash Flow1,906,000,000USD
    Capital Expenditures-376,000,000USD
    Net Investments27,000,000USD
    Other Investing Activities-214,000,000USD
    Unclassified Investing Cash Flow-40,000,000USD
    Investing Cash Flow-603,000,000USD
    Net Debt Issuance-1,955,000,000USD
    Net Common Stock Issuance-2,250,000,000USD
    Common Dividends Paid-875,000,000USD
    Other Financing Activities-70,000,000USD
    Unclassified Financing Cash Flow3,854,000,000USD
    Financing Cash Flow-1,296,000,000USD
    Effect Of Forex Changes On Cash5,000,000USD
    Change In Cash86,000,000USD
    End Cash Flow863,000,000USD
    SourceDisclosureDeterministicFinal

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-03-31 · USDQ1 20262025-12-31 · USDQ4 20252025-09-30 · USDQ1 20252024-12-31 · USDQ3 20242024-06-30 · USDQ2 20242024-03-31 · USDQ1 20242023-12-31 · USDQ3 20232023-06-30 · USD
    Net Income-310,000,000USD382,000,000USD493,000,000USD303,000,000USD487,000,000USD537,000,000USD281,000,000USD407,000,000USD
    Depreciation520,000,000USD614,000,000USD629,000,000USD607,000,000USD568,000,000USD571,000,000USD561,000,000USD571,000,000USD
    Stock Based Compensation58,000,000USD91,000,000USD55,000,000USD90,000,000USD53,000,000USD60,000,000USD83,000,000USD56,000,000USD
    Other Non Cash Items75,000,000USD47,000,000USD146,000,000USD214,000,000USD65,000,000USD-5,000,000USD-145,000,000USD43,000,000USD
    Change In Working Capital415,000,000USD-415,000,000USD250,000,000USD-370,000,000USD241,000,000USD-590,000,000USD152,000,000USD102,000,000USD
    Total Cash From Operating Activities671,000,000USD657,000,000USD1,354,000,000USD693,000,000USD1,264,000,000USD515,000,000USD841,000,000USD1,080,000,000USD
    Capital Expenditures-125,000,000USD-108,000,000USD-352,000,000USD-105,000,000USD-179,000,000USD-134,000,000USD-116,000,000USD-191,000,000USD
    Free Cash Flow546,000,000USD549,000,000USD1,002,000,000USD588,000,000USD1,085,000,000USD381,000,000USD725,000,000USD889,000,000USD
    Investments23,000,000USD0USD14,000,000USD204,000,000USD-288,000,000USD-1,056,000,000USD-233,000,000USD-329,000,000USD
    Total Cashflows From Investing Activities-139,000,000USD-183,000,000USD-494,000,000USD204,000,000USD-288,000,000USD-1,056,000,000USD-233,000,000USD-329,000,000USD
    Net Borrowings-1,989,000,000USD317,000,000USD-258,000,000USD-800,000,000USD———-1,503,000,000USD
    Total Cash From Financing Activities-414,000,000USD-302,000,000USD-809,000,000USD-1,928,000,000USD1,120,000,000USD1,705,000,000USD-862,000,000USD-1,793,000,000USD
    Dividends Paid-290,000,000USD-299,000,000USD-297,000,000USD-302,000,000USD-275,000,000USD-275,000,000USD-275,000,000USD-286,000,000USD
    Sale Purchase Of Stock250,000,000USD-250,000,000USD-250,000,000USD-750,000,000USD0USD0USD-500,000,000USD—
    Change In Cash120,000,000USD173,000,000USD53,000,000USD-1,043,000,000USD2,093,000,000USD1,160,000,000USD-247,000,000USD-1,044,000,000USD
    Begin Period Cash Flow1,024,000,000USD851,000,000USD798,000,000USD1,856,000,000USD2,394,000,000USD1,234,000,000USD1,481,000,000USD2,068,000,000USD
    End Period Cash Flow1,144,000,000USD1,024,000,000USD851,000,000USD813,000,000USD4,487,000,000USD2,394,000,000USD1,234,000,000USD1,024,000,000USD
    Other Cashflows From Investing Activities-37,000,000USD-75,000,000USD-142,000,000USD-94,000,000USD-94,000,000USD-107,000,000USD-117,000,000USD-138,000,000USD
    Other Cashflows From Financing Activities-374,000,000USD-70,000,000USD-4,000,000USD-76,000,000USD-8,000,000USD8,000,000USD-87,000,000USD-320,000,000USD
    Unclassified Operating Cash Flow-87,000,000USD-62,000,000USD-219,000,000USD-151,000,000USD-150,000,000USD-58,000,000USD-91,000,000USD-99,000,000USD
    Unclassified Financing Cash Flow1,989,000,000USD———1,403,000,000USD1,972,000,000USD—316,000,000USD
    Unclassified Investing Cash Flow——-14,000,000USD199,000,000USD273,000,000USD241,000,000USD233,000,000USD329,000,000USD
    Change To Account Receivables—————361,000,000USD—215,000,000USD
    Change To Liabilities———————0USD
    Cash And Cash Equivalents Changes———————-1,042,000,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-09-30 · USDFY 20242024-09-30 · USDFY 20222022-09-30 · USDFY 20212021-09-30 · USDFY 20202020-09-30 · USDFY 20192019-09-30 · USDFY 20182018-09-30 · USDFY 20172017-09-30 · USD
    Net Income1,678,000,000USD1,705,000,000USD1,779,000,000USD2,092,000,000USD874,000,000USD1,220,000,000USD311,000,000USD1,100,000,000USD
    Depreciation2,462,000,000USD2,286,000,000USD2,229,000,000USD2,273,000,000USD2,154,000,000USD2,253,000,000USD1,978,000,000USD1,088,000,000USD
    Stock Based Compensation258,000,000USD247,000,000USD233,000,000USD237,000,000USD244,000,000USD261,000,000USD322,000,000USD174,000,000USD
    Other Non Cash Items306,000,000USD-522,000,000USD-94,000,000USD67,000,000USD57,000,000USD120,000,000USD-403,000,000USD795,000,000USD
    Change To Account Receivables71,000,000USD-453,000,000USD32,000,000USD-95,000,000USD-48,000,000USD-51,000,000USD-170,000,000USD-93,000,000USD
    Change To Inventory-410,000,000USD98,000,000USD-631,000,000USD-104,000,000USD-125,000,000USD-149,000,000USD246,000,000USD-46,000,000USD
    Change In Working Capital-800,000,000USD293,000,000USD-1,394,000,000USD282,000,000USD512,000,000USD-143,000,000USD897,000,000USD-371,000,000USD
    Total Cash From Operating Activities3,430,000,000USD3,798,000,000USD2,633,000,000USD4,647,000,000USD3,539,000,000USD3,330,000,000USD2,865,000,000USD2,550,000,000USD
    Capital Expenditures-760,000,000USD-725,000,000USD-973,000,000USD-1,231,000,000USD-810,000,000USD-957,000,000USD-895,000,000USD-727,000,000USD
    Free Cash Flow2,670,000,000USD3,072,000,000USD1,660,000,000USD3,416,000,000USD2,729,000,000USD2,373,000,000USD1,970,000,000USD1,823,000,000USD
    Investments-818,000,000USD-5,514,000,000USD-3,231,000,000USD-1,880,000,000USD-1,232,000,000USD-741,000,000USD11,000,000USD13,000,000USD
    Total Cashflows From Investing Activities-818,000,000USD-5,514,000,000USD-3,220,000,000USD-1,880,000,000USD-1,232,000,000USD-741,000,000USD-15,829,000,000USD-883,000,000USD
    Net Borrowings-1,334,000,000USD3,775,000,000USD-78,000,000USD-243,000,000USD-1,760,000,000USD-2,035,000,000USD1,090,000,000USD7,282,000,000USD
    Total Cash From Financing Activities-3,617,000,000USD2,087,000,000USD-591,000,000USD-3,306,000,000USD22,000,000USD-3,224,000,000USD-57,000,000USD10,978,000,000USD
    Dividends Paid-1,196,000,000USD-1,100,000,000USD-1,082,000,000USD-1,048,000,000USD-1,026,000,000USD-984,000,000USD-927,000,000USD-677,000,000USD
    Sale Purchase Of Stock-1,000,000,000USD-500,000,000USD-500,000,000USD-1,750,000,000USD3,389,000,000USD2,224,000,000USD0USD-220,000,000USD
    Change In Cash-1,005,000,000USD375,000,000USD-1,233,000,000USD-525,000,000USD2,327,000,000USD-646,000,000USD-13,039,000,000USD12,638,000,000USD
    Begin Period Cash Flow1,856,000,000USD1,481,000,000USD2,392,000,000USD2,917,000,000USD590,000,000USD1,236,000,000USD14,179,000,000USD1,541,000,000USD
    End Period Cash Flow851,000,000USD1,856,000,000USD1,159,000,000USD2,392,000,000USD2,917,000,000USD590,000,000USD1,140,000,000USD14,179,000,000USD
    Other Cashflows From Investing Activities-480,000,000USD-444,000,000USD-177,000,000USD-141,000,000USD-421,000,000USD-261,000,000USD-1,093,000,000USD-887,000,000USD
    Other Cashflows From Financing Activities-87,000,000USD-88,000,000USD1,796,000,000USD-265,000,000USD-109,000,000USD-204,000,000USD-220,000,000USD-234,000,000USD
    Unclassified Operating Cash Flow-474,000,000USD-211,000,000USD-120,000,000USD-304,000,000USD-302,000,000USD-381,000,000USD-240,000,000USD-236,000,000USD
    Unclassified Investing Cash Flow1,240,000,000USD1,169,000,000USD1,161,000,000USD1,372,000,000USD1,231,000,000USD1,218,000,000USD-13,852,000,000USD718,000,000USD
    Change To Liabilities——-473,000,000USD687,000,000USD205,000,000USD-470,000,000USD604,000,000USD218,000,000USD
    Issuance Of Capital Stock——0USD0USD2,917,000,000USD485,000,000USD——
    Cash And Cash Equivalents Changes——-1,485,000,000USD-539,000,000USD2,329,000,000USD—-13,039,000,000USD12,638,000,000USD
    Unclassified Financing Cash Flow——-727,000,000USD—-472,000,000USD-2,225,000,000USD—4,827,000,000USD
    Exchange Rate Changes——————-17,000,000USD-6,000,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    Consumables Minimum Purchase Commitment RPO

    Period endPeriodValueUnitSource
    2026-06-30instant2,000,000,000USDDisclosure

    Products and Services Remaining Performance Obligations

    Period endPeriodValueUnitSource
    2026-06-30instant2,300,000,000USDDisclosure

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q3 2026Quarterly · 2026-06-30GeographyInternational1,902,000,000USDDisclosure
    Q3 2026Quarterly · 2026-06-30GeographyUnited States3,081,000,000USDDisclosure
    Q3 2026Quarterly · 2026-06-30SegmentBio Pharma Systems670,000,000USDDisclosure
    Q3 2026Quarterly · 2026-06-30SegmentConnected Care1,224,000,000USDDisclosure
    Q3 2026Quarterly · 2026-06-30SegmentInterventional1,414,000,000USDDisclosure
    Q3 2026Quarterly · 2026-06-30SegmentMedical Essentials1,675,000,000USDDisclosure
    Q2 2026Quarterly · 2026-03-31GeographyInternational1,797,000,000USD0000010795-26-000026
    Q2 2026Quarterly · 2026-03-31GeographyUnited States2,917,000,000USD0000010795-26-000026
    Q2 2026Quarterly · 2026-03-31SegmentBio Pharma Systems590,000,000USD0000010795-26-000026
    Q2 2026Quarterly · 2026-03-31SegmentConnected Care1,120,000,000USD0000010795-26-000026
    Q2 2026Quarterly · 2026-03-31SegmentInterventional1,357,000,000USD0000010795-26-000026
    Q2 2026Quarterly · 2026-03-31SegmentMedical Essentials1,647,000,000USD0000010795-26-000026
    Q1 2026Quarterly · 2025-12-31GeographyInternational2,093,000,000USD0000010795-26-000005
    Q1 2026Quarterly · 2025-12-31GeographyUnited States3,159,000,000USD0000010795-26-000005
    Q1 2026Quarterly · 2025-12-31SegmentBio Pharma Systems429,000,000USD0000010795-26-000005
    Q1 2026Quarterly · 2025-12-31SegmentConnected Care1,131,000,000USD0000010795-26-000005
    Q1 2026Quarterly · 2025-12-31SegmentInterventional1,330,000,000USD0000010795-26-000005
    Q1 2026Quarterly · 2025-12-31SegmentLife Sciences766,000,000USD0000010795-26-000005
    Q1 2026Quarterly · 2025-12-31SegmentMedical Essentials1,595,000,000USD0000010795-26-000005
    Q4 2025Quarterly · 2025-09-30SegmentInterventional1,368,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-09-30SegmentLife Sciences1,369,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-09-30SegmentMedical3,154,000,000USDLegacy provider
    FY 2025Yearly · 2025-09-30SegmentInterventional5,217,000,000USD0000010795-25-000099
    FY 2025Yearly · 2025-09-30SegmentLife Sciences5,167,000,000USD0000010795-25-000099
    FY 2025Yearly · 2025-09-30SegmentMedical11,456,000,000USD0000010795-25-000099
    Q3 2025Quarterly · 2025-06-30GeographyInternational2,328,000,000USD0000010795-25-000072
    Q3 2025Quarterly · 2025-06-30GeographyUnited States3,181,000,000USD0000010795-25-000072
    Q3 2025Quarterly · 2025-06-30SegmentInterventional1,328,000,000USD0000010795-25-000072
    Q3 2025Quarterly · 2025-06-30SegmentLife Sciences1,254,000,000USD0000010795-25-000072
    Q3 2025Quarterly · 2025-06-30SegmentMedical2,927,000,000USD0000010795-25-000072
    Q2 2025Quarterly · 2025-03-31GeographyInternational1,704,000,000USD0000010795-26-000026
    Q2 2025Quarterly · 2025-03-31GeographyUnited States2,776,000,000USD0000010795-26-000026
    Q2 2025Quarterly · 2025-03-31SegmentBio Pharma Systems575,000,000USD0000010795-26-000026
    Q2 2025Quarterly · 2025-03-31SegmentConnected Care1,068,000,000USD0000010795-26-000026
    Q2 2025Quarterly · 2025-03-31SegmentInterventional1,264,000,000USD0000010795-26-000026
    Q2 2025Quarterly · 2025-03-31SegmentMedical Essentials1,573,000,000USD0000010795-26-000026
    Q1 2025Quarterly · 2024-12-31GeographyInternational2,089,000,000USD0000010795-26-000005
    Q1 2025Quarterly · 2024-12-31GeographyUnited States3,080,000,000USD0000010795-26-000005
    Q1 2025Quarterly · 2024-12-31SegmentBio Pharma Systems418,000,000USD0000010795-26-000005
    Q1 2025Quarterly · 2024-12-31SegmentConnected Care1,073,000,000USD0000010795-26-000005
    Q1 2025Quarterly · 2024-12-31SegmentInterventional1,257,000,000USD0000010795-26-000005
    Q1 2025Quarterly · 2024-12-31SegmentLife Sciences836,000,000USD0000010795-26-000005
    Q1 2025Quarterly · 2024-12-31SegmentMedical Essentials1,586,000,000USD0000010795-26-000005
    FY 2024Yearly · 2024-09-30SegmentInterventional4,980,000,000USD0000010795-25-000099
    FY 2024Yearly · 2024-09-30SegmentLife Sciences5,191,000,000USD0000010795-25-000099
    FY 2024Yearly · 2024-09-30SegmentMedical10,074,000,000USD0000010795-25-000099
    Q3 2024Quarterly · 2024-06-30GeographyInternational2,098,000,000USD0000010795-25-000072
    Q3 2024Quarterly · 2024-06-30GeographyUnited States2,891,000,000USD0000010795-25-000072
    Q2 2024Quarterly · 2024-03-31GeographyInternational2,139,000,000USD0000010795-25-000039
    Q2 2024Quarterly · 2024-03-31GeographyUnited States2,906,000,000USD0000010795-25-000039
    Q2 2024Quarterly · 2024-03-31SegmentInterventional1,292,000,000USD0000010795-25-000039
    Q2 2024Quarterly · 2024-03-31SegmentLife Sciences1,304,000,000USD0000010795-25-000039
    Q2 2024Quarterly · 2024-03-31SegmentMedical2,449,000,000USD0000010795-25-000039
    FY 2023Yearly · 2023-09-30SegmentInterventional4,736,000,000USD0000010795-25-000099
    FY 2023Yearly · 2023-09-30SegmentLife Sciences5,133,000,000USD0000010795-25-000099
    FY 2023Yearly · 2023-09-30SegmentMedical9,502,000,000USD0000010795-25-000099
    FY 2022Yearly · 2022-09-30SegmentInterventional4,464,000,000USD0000010795-24-000084
    FY 2022Yearly · 2022-09-30SegmentLife Sciences5,564,000,000USD0000010795-24-000084
    FY 2022Yearly · 2022-09-30SegmentMedical8,841,000,000USD0000010795-24-000084
    FY 2021Yearly · 2021-09-30SegmentInterventional4,239,000,000USD0000010795-23-000098
    FY 2021Yearly · 2021-09-30SegmentLife Sciences6,530,000,000USD0000010795-23-000098
    FY 2021Yearly · 2021-09-30SegmentMedical8,361,000,000USD0000010795-23-000098
    FY 2020Yearly · 2020-09-30SegmentInterventional3,762,000,000USD0001628280-22-030686
    FY 2020Yearly · 2020-09-30SegmentLife Sciences4,675,000,000USD0001628280-22-030686
    FY 2020Yearly · 2020-09-30SegmentMedical7,637,000,000USD0001628280-22-030686
    FY 2019Yearly · 2019-09-30SegmentInterventional3,926,000,000USD0000010795-21-000091
    FY 2019Yearly · 2019-09-30SegmentLife Sciences4,300,000,000USD0000010795-21-000091
    FY 2019Yearly · 2019-09-30SegmentMedical9,064,000,000USD0000010795-21-000091
    FY 2018Yearly · 2018-09-30SegmentInterventional3,037,000,000USD0000010795-20-000055
    FY 2018Yearly · 2018-09-30SegmentLife Sciences4,330,000,000USD0000010795-20-000055
    FY 2018Yearly · 2018-09-30SegmentMedical8,616,000,000USD0000010795-20-000055
    FY 2018Yearly · 2018-09-30GeographyAsia2,460,000,000USD0000010795-18-000036
    FY 2018Yearly · 2018-09-30GeographyEurope3,298,000,000USD0000010795-18-000036
    FY 2018Yearly · 2018-09-30GeographyOthers Country1,457,000,000USD0000010795-18-000036
    FY 2018Yearly · 2018-09-30GeographyUnited States8,768,000,000USD0000010795-18-000036
    FY 2017Yearly · 2017-09-30GeographyAsia1,744,000,000USD0000010795-18-000036
    FY 2017Yearly · 2017-09-30GeographyEurope2,588,000,000USD0000010795-18-000036
    FY 2017Yearly · 2017-09-30GeographyOthers Country1,257,000,000USD0000010795-18-000036
    FY 2017Yearly · 2017-09-30GeographyUnited States6,504,000,000USD0000010795-18-000036
    FY 2016Yearly · 2016-09-30GeographyAsia1,692,000,000USD0000010795-18-000036
    FY 2016Yearly · 2016-09-30GeographyEurope2,674,000,000USD0000010795-18-000036
    FY 2016Yearly · 2016-09-30GeographyOthers Country1,225,000,000USD0000010795-18-000036
    FY 2016Yearly · 2016-09-30GeographyUnited States6,893,000,000USD0000010795-18-000036
    FY 2015Yearly · 2015-09-30GeographyAsia1,545,000,000USD0000010795-17-000021
    FY 2015Yearly · 2015-09-30GeographyEurope2,434,000,000USD0000010795-17-000021
    FY 2015Yearly · 2015-09-30GeographyOthers Country1,234,000,000USD0000010795-17-000021
    FY 2015Yearly · 2015-09-30GeographyUnited States5,069,000,000USD0000010795-17-000021
    FY 2014Yearly · 2014-09-30GeographyAsia1,437,000,000USD0001628280-16-021658
    FY 2014Yearly · 2014-09-30GeographyEurope2,383,000,000USD0001628280-16-021658
    FY 2014Yearly · 2014-09-30GeographyOthers Country1,210,000,000USD0001628280-16-021658
    FY 2014Yearly · 2014-09-30GeographyUnited States3,417,000,000USD0001628280-16-021658
    FY 2013Yearly · 2013-09-30GeographyAsia1,344,000,000USD0001628280-15-008984
    FY 2013Yearly · 2013-09-30GeographyEurope2,189,000,000USD0001628280-15-008984
    FY 2013Yearly · 2013-09-30GeographyOthers Country1,168,000,000USD0001628280-15-008984
    FY 2013Yearly · 2013-09-30GeographyUnited States3,353,000,000USD0001628280-15-008984
    FY 2012Yearly · 2012-09-30GeographyAsia Pacific883,000,000USD0001193125-14-426571
    FY 2012Yearly · 2012-09-30GeographyEurope2,379,000,000USD0001193125-14-426571
    FY 2012Yearly · 2012-09-30GeographyOthers Country1,159,000,000USD0001193125-14-426571
    FY 2012Yearly · 2012-09-30GeographyUnited States3,288,000,000USD0001193125-14-426571
    FY 2011Yearly · 2011-09-30GeographyAsia Pacific793,000,000USD0001193125-13-456802

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.